IOL Chemicals and Pharmaceuticals begins commercial production of Paracetamol

Paracetamol, also known as Acetaminophen, is an Active Pharma Ingredient (API) that is used to treat fever and mild pain.

Published On 2022-04-25 05:00 GMT   |   Update On 2022-04-25 12:02 GMT

Punjab: IOL Chemicals and Pharmaceuticals Limited has announced that the company has commenced the commercial production of 'Paracetamol' with installed capacity of 1800 MTPA along with backward integration of Para Amino Phenol (PAP) with effect from 22 nd April 2022.The Company is manufacturing Paracetamol in its existing Unit No 4, which has been converted as multiproduct facility, with...

Login or Register to read the full article

Punjab: IOL Chemicals and Pharmaceuticals Limited has announced that the company has commenced the commercial production of 'Paracetamol' with installed capacity of 1800 MTPA along with backward integration of Para Amino Phenol (PAP) with effect from 22 nd April 2022.

The Company is manufacturing Paracetamol in its existing Unit No 4, which has been converted as multiproduct facility, with a cost of about Rs 100 Lakhs whereas PAP is being manufactured in part of Unit No 9. The Company shall continue to use Unit 4 & Unit 9 for manufacturing other products as per market conditions.

Further, considering the present market scenario, the Company is in the process of enhancing the installed capacity for manufacturing the Paracetamol from 1800 MTPA to 3600 MTPA with a capex of about Rs 25 Crore, which is expected to be completed during the 3 rd quarter of FY 2023. All the capex is being met through internal accruals only.

The Paracetamol, also known as Acetaminophen, is an Active Pharma ingredient (API) that is used to treat fever and mild pain, whereas PAP is used as an intermediate to manufacture Paracetamol.

Read also: IOL Chemicals gets Korean approval for Ibuprofen, Fenofibrate

IOL Chemicals and Pharmaceuticals Limited is an innovation-driven Bulk Drug, Intermediates and Specialty Chemicals Company headquartered in India. Its APIs portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. The company is the backward integrated company producing all Intermediates and Key Starting Materials (KSMs) of ibuprofen.

Read also: USFDA gives its nod to IOL chemicals and pharmaceuticals for a plant in Punjab

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News